Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 68 Neoplasms 25 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 13 Lung Neoplasms 12 Head and Neck Neoplasms 11 Neoplasm Metastasis 8 Carcinoma, Squamous Cell 7 Pancreatic Neoplasms 6 Colorectal Neoplasms 6 Stomach Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Prostatic Neoplasms 4 Multiple Myeloma 4 Esophageal Neoplasms 4 Lymphoma 3 Hematologic Neoplasms 3 Glioblastoma 3 Brain Neoplasms 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Solid Tumors 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 NSCLC 2 Melanoma 2 Glioma 2 Colonic Neoplasms 2 Adenocarcinoma of Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1

Interventions

Gemcitabine 9 pembrolizumab 7 Cisplatin 5 enfortumab vedotin 4 atezolizumab 4 Trastuzumab 4 Mitomycin 4 Carboplatin 4 Sunitinib 3 Pemetrexed 3 dodecyl maltoside 2 cabozantinib 2 Water 2 Sugammadex 2 Standard of Care 2 Saline Solution 2 Paclitaxel 2 Nivolumab 2 Neostigmine 2 Docetaxel 2 Cetuximab 2 Bevacizumab 2 zidovudine 5'-monophosphate-mannose-albumin conjugate 1 vinflunine 1 valrubicin 1 tucatinib 1 tislelizumab 1 testosterone 17 beta-cypionate 1 temsirolimus 1 relatlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urologic Neoplasms × Afatinib × Clear all

NCT02780687 2020-11-18

LUX-Bladder 1

Boehringer Ingelheim

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡